Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 Diabetes

NCT00395746 · Completed

Last updated 2026-05-28

This clinical trial tested whether adding the medication liraglutide to sulfonylurea treatment helps control blood sugar levels in adults with type 2 diabetes over a 24-week period.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 264 people

Who can join Ages 20+ · all sexes

Timeline Started 2006-10 · est. completion 2008-05

Where 1 site · Japan

What this study is testing ClinicalTrials.gov NCT00395746 ↗

Description as written by the study sponsor.

This trial is conducted in Japan. The trial aims for comparison of the effect on glycaemic control of liraglutide in combination with sulphonylurea agent (SU) compared to SU monotherapy, as assessed by HbA1c after 24 weeks and 52 weeks in subjects with type 2 diabetes. Liraglutide will be compared to placebo, in combination with SU. Trial has a randomisation period of 24 weeks followed by a 28 week extension period, in total 52 weeks.

Treatments tested

sulfonylurea Drug

SU agent
liraglutide Drug

Liraglutide 0.6 mg/day or placebo. Injected s.c. (under the skin) once daily.
liraglutide Drug

Liraglutide 0.9 mg/day or placebo. Injected s.c. (under the skin) once daily.

Main thing measured	Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00395746 ↗